By Edward Winnick

NEW YORK (GenomeWeb News) - Fluidigm officials said Monday that the firm is focusing on growing its business and inking partnerships as it keeps its eye on a potential initial public offering.

The microfluidics and array manufacturer was forced to withdraw its proposed IPO amid the market meltdown a year ago. At the time, company officials said that Fluidigm would go public once the markets stabilized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.